GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2012

Novel Treatment for Most Common Type of Lung Cancer

  • The FDA OK’d Celgene’s Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. The drug was approved for use in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

    “Non-small cell is the most common type of lung cancer, the leading cause of cancer death in the United States,” said Mark A. Socinski, M.D., director, lung cancer section, division of hematology/oncology, University of Pittsburgh, and lead investigator of Abraxane Phase II and Phase III lung cancer trials. “The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung cancer patients, in an area that has seen few treatment advancements in recent years.”

    Celgene has filed additional regulatory submissions for the product in Japan, Australia, and New Zealand. This approval marks the second indication for Abraxane in the U.S. where the drug was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy.

    According to Genomic Health, the incidence of non-small cell lung cancer totals about 171,000 cases per year.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?